September 9, 2021
Apexigen Announces Appointment of Dr. Frank Hsu as Chief Medical Officer

September 7, 2021
Apexigen to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

August 5, 2021
Apexigen Receives Orphan Drug Designation from the FDA for Sotigalimab (APX005M) for the Treatment of Soft Tissue Sarcoma

August 2, 2021
Apexigen to Participate in the 2021 Wedbush PacGrow Healthcare Conference

July 8, 2021
Apexigen to Participate in Upcoming Investor Conferences

June 16, 2021
Apexigen and the Nordic Society of Gynaecological Oncology – Clinical Trial Unit Announce Collaborative Phase 2 Study of Sotigalimab (APX005M) in Combination Therapy for Ovarian Cancer

May 19, 2021
Apexigen Announces Presentation of Phase 2 Clinical Data on CD40 Antibody, Sotigalimab (APX005M), in Combination Therapy for Metastatic Pancreatic Cancer at the ASCO 2021 Annual Meeting

April 9, 2021
Apexigen Announces Presentations of Preclinical Data for its TNFR2 Antagonist (APX601) and SIRPα Antagonist (APX701) Programs at the AARC Annual Meeting 2021

March 1, 2021
Apexigen to Present at Investor Conferences in March and April 2021

January 19, 2021
Apexigen publishes Sotigalimab/APX005M preclinical results in Cancer Immunology, Immunotherapy in an article entitled: “APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application”

January 7, 2021
Apexigen to Present at Virtual Investor Conferences

January 2021
The Parker Institute for Cancer Immunotherapy (PICI) publishes clinical trial results in The Lancet Oncology in an article entitled: CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study


November 9, 2020
Apexigen Announces First Preclinical Data Presentation on Novel Anti-TNFR2 and Anti-SIRPα Antibody Programs at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 15, 2020
Apexigen’s APX005M Granted Orphan Drug Designations for the Treatment of Esophageal and Gastroesophageal Junction Cancer and for the Treatment of Pancreatic Cancer

October 13, 2020
Apexigen to Present at Solebury Trout Fall 2020 Virtual Private Company Showcase

August 19, 2020
Apexigen Appoints Jakob Dupont to Board of Directors

June 4, 2020
Apexigen Appoints Gordon Ringold to its Board of Directors

March 26, 2020
Apexigen To Present At The Upcoming 2020 Solebury Trout Virtual Investor Conference

March 24, 2020
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline

February 27, 2020
Apexigen To Present At Upcoming Investor Conferences


December 6, 2019
Apexigen Expands Leadership Team with Two Key Appointments in CMC and Clinical Development

October 16, 2019
Apexigen’s CEO, Xiaodong Yang, Recognized Among 100 Most Intriguing Entrepreneurs at Goldman Sachs 2019 Builders + Innovators Summit

October 16, 2019
Apexigen to Present at the 2019 Solebury Trout Private Company Showcase

October 9, 2019
Apexigen Appoints Biotechnology Financial Executive Herb Cross to Board of Directors

Sept 24, 2019
Apexigen Announces Participation In Upcoming Oncology Conferences

Sept 4, 2019
Apexigen Appoints Scott Smith to Board of Directors

April 1, 2019
Apexigen Presents Clinical Data on CD40 Antibody APX005M in Metastatic Melanoma at the AACR Annual Meeting 2019

March 31, 2019
Apexigen Announces New Clinical Data on APX005M in Combination Therapy for Pancreatic Cancer at the AACR Annual Meeting 2019

March 20, 2019
Apexigen Announces Clinical Data Presentations on CD40 Antibody APX005M at the AACR Annual Meeting 2019

February 19, 2019
Apexigen to present at upcoming Investor Conferences


December 20, 2018 
Apexigen announces Clinical Collaboration on a New Phase 2 Trial For APX005M in Sarcoma

December 6, 2018
Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon’s NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma

November 26, 2018
Apexigen To Present At Piper Jaffray’s 30th Annual Healthcare Conference

August 8, 2018
Apexigen Raises $73 Million In Series B And Series C Financings

June 14, 2018
Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy

May 18, 2018
Apexigen Expands Leadership Team with Appointment of Frances Rena Bahjat, Ph.D. Vice President, Discovery Research

March 6, 2018
Apexigen and the Pediatric Brain Tumor Consortium Announce a Clinical Collaboration to Evaluate APX005M in Children with Brain Tumors
Study to evaluate the safety and tolerability of APX005M, a CD40 agonistic antibody, in pediatric patients with recurrent or refractory brain tumors


October 31, 2017
Apexigen Announces Late-Breaking Oral Presentation for Immune Activating Antibody APX005M at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 25, 2017
Apexigen Announces New Collaboration with UCSF
Clinical Trial Collaboration to Evaluate Apexigen’s Immune Activating Antibody APX005M in Combination with Multimodality Treatment of Resectable Esophageal and Gastro-Esophageal Junction Cancers

September 20, 2017
The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute Announce First Patients Treated in Pancreatic Cancer Clinical Trial Combining Immunotherapy and Chemotherapy
Collaboration with Bristol-Myers Squibb, Apexigen will test CD40 antibody APX005M, nivolumab and chemotherapy

July 25, 2017
Neon Therapeutics and Apexigen Announce Immuno-Oncology Clinical Trial Collaboration 

July 17, 2017
Apexigen, Inc. Announces First Patient Dosed in Phase 1b/2 Clinical Trial of APX005M in Combination with Opdivo (nivolumab) in Advanced Solid Tumors

April 11, 2017
Bristol-Myers Squibb and Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with APX005M in Advanced Solid Tumors

March 21, 2017
Phase 1/2 Clinical Trial of Apexigen’s APX005M in Combination with Pembrolizumab (Keytruda®) Opens for Metastatic Melanoma Patients

March 16, 2017
Apexigen Receives Clinical Development Milestone Payment under Collaboration Agreement


April 13, 2016
Apexigen to Present Data on Its Novel Immuno-Oncology Program APX005M at Upcoming Cancer Conferences


November 17, 2015
Apexigen Presents Positive Data for APX005M in Podium Presentation at Immune Checkpoint Inhibitors (ICI) Europe

November 06, 2015
Apexigen Presents Preclinical Data from Novel Immuno-Oncology Candidate APX005M at SITC 2015 Meeting

June 22, 2015
3SBio Acquires Global Rights to Anti-TNF mAb Acquisition expands international product pipeline

June 16, 2015
Apexigen Doses First Patient in Phase 1 Clinical Trial of Its Immuno-oncology Therapeutic Antibody APX005M

May 06, 2015
Apexigen Selected to Present at Cavendish Global Health Impact Forum


October 15, 2014
Apexigen Strengthens its Management Team with Additions of Vice President, Clinical Development and Vice President, Finance

Apexigen ranked #4 among US Life Science Start-up Companies by BioSpace (pdf)

October 18, 2013
Apexigen listed in the Top 20 of the 2013 Biotech Start-up Class of 2013 by Xconomy (pdf)

August 6, 2013
Apexigen Secures $20 Million Series A1 Financing


December 5, 2012
Boehringer Ingelheim and Apexigen sign manufacturing agreement for process development and early stage clinical supply

November 11, 2012
Apexigen Announces Initiation of Clincal Trials by Its Partner, Simcere Pharmaceutical Group

August 15, 2012
Apexigen Announces the Filing of an IND by its Partner, 3SBio

April 2012
Apexigen Inc. is Using Antibodies Derived from Rabbits to Develop Therapies in Cancer and Inflammatory Disease (pdf)

March 6, 2012
Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004

March 11, 2011
Apexigen Announces the Filing by its Partner, Simcere Pharmaceutical Group, of First IND

December 7, 2010
Apexigen, Inc. Announces Collaboration for Antibody Discovery

November 22, 2010
BioCentury: Emerging Company Profile - Apexigen: rAbbits hop rodents (pdf)